

# Deal Release



cyril amarchand mangaldas  
ahead of the curve

## **Cyril Amarchand Mangaldas advises Organon & Co., a global healthcare company, in its acquisition by Sun Pharmaceutical Holdings USA, Inc.**

**April 27, 2026, Mumbai:** Cyril Amarchand Mangaldas advised Organon & Co. (NYSE: OGN), a global healthcare company, with diverse portfolio across women's health, biosimilars, and therapies and products for a wide range of conditions and diseases, in its acquisition by Sun Pharmaceutical Holdings USA, Inc., a U.S. subsidiary of Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA), the leading pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.

The transaction team was led by **Ruetvej Pandya**, *Partner*, and **Saloni Shroff**, *Partner*, with assistance from **Abhilasha Malpani**, *Principal Associate*; **Sajith Anjickal**, **Chelsea Sawlani**, **Neelanshi Gupta**, **Simran Srivastava**, and **Shravan Subramanian**, *Associates*.

**Rishabh Shroff**, *Partner (Co-Head - Private Client and Head - International Business Development)*; provided strategic inputs and guidance.

**Meeta Kurpad**, *Partner*; with support from **Manasvin Andra**, *Associate*; advised on financing aspects of the transaction.